Author/Authors :
Hajiahmadi, Mahmoud Department of Biostatistics and Epidemiology - Babol University of Medical Sciences - Babol, Iran , Jafari Vesiehsari, Mahjoobeh epartment of Biostatistics and Epidemiology - Babol University of Medical Sciences - Babol, Iran , Askarian-Amiri, Shaghayegh Cellular and Molecular Biology Research Center - Health Research Institute - Babol University of Medical Sciences - Babol, Iran , Ordoni Aval, Farzane Cellular and Molecular Biology Research Center - Health Research Institute - Babol University of Medical Sciences - Babol, Iran , Azadmehr, Abbas Cellular and Molecular Biology Research Center - Health Research Institute - Babol University of Medical Sciences - Babol, Iran , Oladnabi, Morteza Ischemic Disorders Research Center - Golestan University of Medical Sciences - Gorgan, Iran
Abstract :
Background: T-lineage acute lymphoblastic leukemia (T-ALL) is a malignant hyperplastic disease of the hematopoietic system. This
tumor is the most common tumor in children and adolescents. Myeloid cell leukemia-1 (Mcl-1) is described as a prosurvival protein
from the Bcl2 family. It is an important factor in routine cancer treatments. In fact, in different types of cancers, Mcl-1 downregulation
can be a potential target.
Objectives: The present study aims to evaluate the cytotoxic effect of MCL-1 siRNA in T-ALL cells.
Methods: The present study evaluated the effects of Mcl-1 small interfering RNAs (siRNAs) on survival in Jurkat cells. Specific Mcl-1
siRNA was transfected and using quantitative real-time PCR, the relative expression of Mcl-1 mRNA was determined. Moreover, cell
survival was determined using the colorimetric MTT assay.
Results: The expression of mRNA reduced effectively in a dose-dependent manner at 48 hours after transfection with Mcl-1 siRNA.
In addition, Mcl-1 siRNA treatment could significantly reduce tumor cell survival.
Conclusions: Based on the results, downregulation of Mcl-1 by specific siRNAs in T-ALL cells can effectively reduce cell survival.
Therefore, Mcl-1 siRNA may be a complementary agent along with standard methods in the treatment of T-ALL.
Keywords :
T-ALL , Jurkat Cell Line , siRNA , Mcl-1
